AB-002 is under clinical development by Aronora and currently in Phase II for Thrombosis. According to GlobalData, Phase II drugs for Thrombosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-002 overview
AB002 (E-WE Thrombin) is under development for the treatment of thrombosis in end stage renal disease patients on chronic hemodialysis. It is administered through intravenous bolus. The bioengineered drug candidate targets protein C. The drug candidate is a recombinant antithrombotic and cytoprotective enzyme that acts without increasing the risk of bleeding. It was also under development for the treatment of high bleeding risk indications, such as acute stroke and heart attack, arterial thrombosis, multiple sclerosis, acute cardiovascular ischemia, cerebral ischemia.
See Also:
Aronora overview
Aronora operates in pharmaceutical and healthcare industry. It is headquartered in United States.
For a complete picture of AB-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
